Jung-min Lee

Trials

Studies that name Jung-min Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04739800 · Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

  National Cancer Institute (NCI) · active not recruiting · Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma · principal investigator
• Ph2
  NCT02889900 · Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

  AstraZeneca · completed · Recurrent Platinum Resistant Ovarian Cancer · principal investigator
• Ph2/Ph3
  NCT02502266 · Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

  National Cancer Institute (NCI) · active not recruiting · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma · principal investigator
• Ph2
  NCT02326844 · BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

  National Cancer Institute (NCI) · terminated · Ovarian Cancer · principal investigator
• Ph2
  NCT02203513 · A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

  National Cancer Institute (NCI) · terminated · Ovarian Cancer, Breast Cancer, Prostate Cancer · principal investigator
• Ph1
  NCT01445418 · AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

  National Cancer Institute (NCI) · completed · Breast Cancer, Ovarian Cancer · principal investigator
• Ph1
  NCT01237067 · Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

  National Cancer Institute (NCI) · completed · Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
  ZIABC011525 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2013 to 2025 · $2,194,470 awarded in 2025
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• NRG Oncology Network Group Operations Center
  U10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026
  Named on NCT04739800, NCT02502266